Tag Archives: What’s

Merck analysts to CEO: What’s so great about your pipeline beyond Keytruda?

Sales of Merck & Co.’s immuno-oncology heavy hitter Keytruda soared 66% in the fourth quarter to $ 2.15 billion, surpassing Wall Street’s expectations yet again. But Merck can’t rely solely on one blockbuster’s dutiful performance to drive sales and earnings growth going forward. Analysts’ worries about that fact only intensified on Friday after Merck put… Read More »

Mind: What’s Life Like After Depression? Surprisingly, Little Is Known

ImageCreditScott Menchin A generation ago, depression was viewed as an unwanted guest: a gloomy presence that might appear in the wake of a loss or a grave disappointment and was slow to find the door. The people it haunted could acknowledge the poor company — I’ve been a little depressed since my father died —… Read More »